Mechanisms and treatment of hypercalcemia of malignancy

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 6, 2011, Pages 339-346

  Clines, Gregory A ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

bisphosphonate; bone metastasis; hypercalcemia; malignancy; parathyroid hormonerelated protein

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; GALLIUM NITRATE; IBANDRONIC ACID; MITHRAMYCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PREDNISONE; SODIUM CHLORIDE; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BREAST CANCER; CALCIUM TRANSPORT; CELL TYPE; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; FLUID RESUSCITATION; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; LUNG CANCER; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PARANEOPLASTIC SYNDROME; PRIMARY HYPERPARATHYROIDISM; PROGNOSIS; REVIEW; T CELL LEUKEMIA;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; CALCIUM; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; NEOPLASMS; OSTEOLYSIS; PARATHYROID HORMONE-RELATED PROTEIN; VITAMIN D;

EID: 80255129291     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32834b4401     Document Type: Review

References (102)

1. Grill V, Martin TJ. Hypercalcemia of malignancy. Rev Endocr Metab Disord 2000; 1:253-263.
2. Ralston SH, Gallacher SJ, Patel U, et al. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Inter Med 1990; 112:499-504. (Pubitemid 20100287)
3. Hiraki A, Ueoka H, Takata I, et al. Hypercalcemia-leukocytosis syndrome associated with lung cancer. Lung Cancer 2004; 43:301-307. (Pubitemid 38224150)
4. Mundy GR, Martin TJ. The hypercalcemia of malignancy: pathogenesis and management. Metabolism 1982; 31:1247-1277. (Pubitemid 13223373)
5. Horwitz MJ, Hodak SP, Stewart AF. Nonparathyroid hypercalcemia. In: Rosen, CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008. pp. 307-3012.
6. Carnaille B, Oudar C, Pattou F, et al. Pancreatitis and primary hyperparathyroidism: forty cases. Aust N Z J Surg 1998; 68:117-119. (Pubitemid 28254925)
7. Saikawa T, Tsumabuki S, Nakagawa M, et al. QT intervals as an index of high serum calcium in hypercalcemia. Clin Cardiol 1988; 11:75-78. (Pubitemid 18064959)
8. Wolf ME, Ranade V, Molnar J, et al. Hypercalcemia, arrhythmia, and mood stabilizers. J Clin Psychopharmacol 2000; 20:260-264. (Pubitemid 30202372)
9. Khanna A. Acquired nephrogenic diabetes insipidus. Semin Nephrol 2006; 26:244-248.
10. Earm JH, Christensen BM, Frokiaer J, et al. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol 1998; 9:2181-2193. (Pubitemid 28543796)
11. Moseley JM, Kubota M, Diefenbach-Jagger H, et al. Parathyroid hormonerelated protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A 1987; 84:5048-5052. (Pubitemid 17095861)
12. Strewler GJ, Stern PH, Jacobs JW, et al. Parathyroid hormone-like protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest 1987; 80:1803-1807. (Pubitemid 18007159)
13. Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237:893-896. (Pubitemid 17128278)
14. Hens JR, Wysolmerski JJ. Key stages of mammary gland development: molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Res 2005; 7:220-224. (Pubitemid 41387435)
15. VanHouten JN, Dann P, Stewart AF, et al. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest 2003; 112:1429-1436. (Pubitemid 38057696)
16. Kobayashi T, Chung UI, Schipani E, et al. PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development 2002; 129:2977-2986. (Pubitemid 34874275)
17. Guthalu Kondegowda N, Joshi-Gokhale S, Harb G, et al. Parathyroid hormone-related protein enhances human ss-cell proliferation and function with associated induction of cyclin-dependent kinase 2 and cyclin E expression. Diabetes 2010; 59:3131-3138.
18. Luparello C, Romanotto R, Tipa A, et al. Midregion parathyroid hormonerelated protein inhibits growth and invasion in vitro and tumorigenesis in vivo of human breast cancer cells. J Bone Miner Res 2001; 16:2173-2181. (Pubitemid 33104708)
19. Luparello C. Midregion PTHrP and human breast cancer cells. Scientific-WorldJournal 2010; 10:1016-1028.
20. Fenton AJ, Kemp BE, Hammonds RG Jr, et al. A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of parathyroid hormone-related protein: PTHrP[107-111]. Endocrinology 1991; 129:3424-3426.
21. Zheng MH, McCaughan HB, Papadimitriou JM, et al. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein. J Cell Biochem 1994; 54:145-153. (Pubitemid 24081044)
22. Abou-Samra AB, Juppner H, Force T, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A 1992; 89:2732-2736.
23. Pioszak AA, Parker NR, Gardella TJ, Xu HE. Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem 2009; 284:28382-28391.
24. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451-4458. (Pubitemid 30666108)
25. Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 1992; 90:749-758.
26. Pfister MF, Lederer E, Forgo J, et al. Parathyroid hormone-dependent degradation of type II Na/Pi cotransporters. J Biol Chem 1997; 272:20125-20130. (Pubitemid 27340119)
27. Bikle D, Adams J, Christakos S. Vitamin D: production, metabolism, mechanism of action, and clinical requirements. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008. pp. 141-149.
28. Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993; 76:801-803. (Pubitemid 23086509)
29. Dean T, Vilardaga JP, Potts JT Jr, Gardella TJ. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 2008; 22:156-166.
30. Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 2005; 20:1792-1803. (Pubitemid 41361880)
31. Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990; 322:1106-1112. (Pubitemid 20149527)
32. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373-379.
33. Gallacher SJ, Fraser WD, Patel U, et al. Breast cancer-associated hypercalcaemia: a reassessment of renal calcium and phosphate handling. Ann Clin Biochem 1990; 27 (Pt 6):551-556. (Pubitemid 20377172)
34. Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991; 73:1309-1315. (Pubitemid 121000708)
35. Fraser WD, Robinson J, Lawton R, et al. Clinical and laboratory studies of a new immunoradiometric assay of parathyroid hormone-related protein. Clin Chem 1993; 39:414-419. (Pubitemid 23099005)
36. Pecherstorfer M, Schilling T, Blind E, et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994; 78:1268-1270.
37. Bundred NJ, Walls J, Ratcliffe WA. Parathyroid hormone-related protein, bone metastases and hypercalcaemia of malignancy. Ann R Coll Surg Engl 1996; 78:354-358. (Pubitemid 26241658)
38. Rizzoli R, Thiebaud D, Bundred N, et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999; 84:3545-3550. (Pubitemid 30645203)
39. Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994; 79:1322-1327.
40. Kremer R, Shustik C, Tabak T, et al. Parathyroid-hormone-related peptide in hematologic malignancies. Am J Med 1996; 100:406-411. (Pubitemid 26115194)
41. Ansari K, Clerk A, Patel MH, et al. Hypercalcemia induced by parathyroid hormone-related peptide after treatment of squamous cell carcinoma of oral cavity. J Assoc Physicians India 2003; 51:1023-1024. (Pubitemid 41279854)
42. Gover A, Kumar PD, Brown LA, Ravakhah K. Hypercalcemia induced by parathyroid hormone-related peptide after treatment of carcinoma. South Med J 2002; 95:258-260. (Pubitemid 34136444)
43. Papworth K, Grankvist K, Ljungberg B, Rasmuson T. Parathyroid hormonerelated protein and serum calcium in patients with renal cell carcinoma. Tumour Biol 2005; 26:201-206. (Pubitemid 41379746)
44. Pepper K, Jaowattana U, Starsiak MD, et al. Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature. J Gen Intern Med 2007; 22:1042-1046. (Pubitemid 46878602)
45. Yoshida T, Suzumiya J, Katakami H, et al. Hypercalcemia caused by PTH-rP associated with lung metastasis from urinary bladder carcinoma: an autopsied case. Intern Med 1994; 33:673-676.
46. Cavestro GM, Mantovani N, Coruzzi P, et al. Hypercalcemia due to ectopic secretion of parathyroid related protein from pancreatic carcinoma: a case report. Acta Biomed 2002; 73:37-40.
47. Pun KK, Tam SM. Humoral hypercalcemia of hepatocellular carcinoma associated with elevated levels of parathyroid-hormone-related-peptide. Endocr Pract 1995; 1:166-169.
48. Mantzoros CS, Suva LJ, Moses AC, Spark R. Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour. Clin Endocrinol (Oxf) 1997; 46:373-375. (Pubitemid 27174345)
49. Matsui T, Kageshita T, Ishihara T, et al. Hypercalcemia in a patient with malignant melanoma arising in congenital giant pigmented nevus. A case of increased serum level of parathyroid hormone-related protein. Dermatology 1998; 197:65-68. (Pubitemid 28327843)
50. Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989; 68:976-981. (Pubitemid 19127419)
51. Nielsen PK, Rasmussen AK, Feldt-Rasmussen U, et al. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 1996; 81:3793-3796. (Pubitemid 26339955)
52. Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990; 323:1324-1328. (Pubitemid 20364741)
53. Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 1993; 76:1373-1375. (Pubitemid 23155467)
54. Iguchi H, Miyagi C, Tomita K, et al. Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland. J Clin Endocrinol Metab 1998; 83:2653-2657. (Pubitemid 28493756)
55. Rizzoli R, Pache JC, Didierjean L, et al. A thymoma as a cause of true ectopic hyperparathyroidism. J Clin Endocrinol Metab 1994; 79:912-915. (Pubitemid 24286426)
56. Wong K, Tsuda S,Mukai R, et al. Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia. Endocrine 2005; 27:83-86. (Pubitemid 41112868)
57. VanHouten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 2006; 91:580-583. (Pubitemid 43236929)
58. Fetchick DA, Bertolini DR, Sarin PS, et al. Production of 1,25-dihydroxyvitamin D3 by human T cell lymphotrophic virus-I-transformed lymphocytes. J Clin Invest 1986; 78:592-596. (Pubitemid 16074100)
59. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86:888-894. (Pubitemid 32207511)
60. Hewison M, Kantorovich V, Liker HR, et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res 2003; 18:579-582. (Pubitemid 36241076)
61. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkins disease and non-Hodgkins lymphomas. Blood 1993; 82:1383-1394. (Pubitemid 23263952)
62. Burt ME, Brennan MF. Incidence of hypercalcemia and malignant neoplasm. Arch Surg 1980; 115:704-707. (Pubitemid 10111866)
63. Laffan MA, Talavera JG, Catovsky D. Hypercalcaemia in T cell acute lymphoblastic leukaemia: report of two cases. J Clin Pathol 1986; 39:1143-1146. (Pubitemid 17175073)
64. Evans KN, Taylor H, Zehnder D, et al. Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol 2004; 165:807-813. (Pubitemid 39129288)
65. Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008; 10:e7.
66. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133:565-614.
67. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-1594. (Pubitemid 27444031)
68. des Grottes JM, Dumon JC, Body JJ. Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates. Melanoma Res 2001; 11:477-482.
69. Sultan I, Kraveka JM, Lazarchick J. CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia. Pediatr Blood Cancer 2004; 43:66-69. (Pubitemid 38738273)
70. Shimonodan H, Nagayama J, Nagatoshi Y, et al. Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature. Pediatr Blood Cancer 2005; 45:333-339. (Pubitemid 41077168)
71. Ganesan P, Thulkar S, Gupta R, Bakhshi S. Childhood aleukemic leukemia with hypercalcemia and bone lesions mimicking metabolic bone disease. J Pediatr Endocrinol Metab 2009; 22:463-467.
72. Takasaki H, Kanamori H, Takabayashi M, et al. Non-Hodgkins lymphoma presenting as multiple bone lesions and hypercalcemia. Am J Hematol 2006; 81:439-442. (Pubitemid 43787932)
73. Matsuhashi Y, Tasaka T, Uehara E, et al. Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis. Leuk Lymphoma 2004; 45:397-400. (Pubitemid 38181448)
74. Guise TA, Taylor SD, Yoneda T, et al. PTHrP expression by breast cancer cells enhance osteolytic bone metastases in vivo. J Bone Miner Res 1994; 9:S128.
75. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancermediated osteolysis. J Clin Invest 1996; 98:1544-1549. (Pubitemid 26327863)
76. Gilmore JL, Gonterman RM, Menon K, et al. Reconstitution of amphiregulinepidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Mol Cancer Res 2009; 7:1714-1728.
77. Miki T, Yano S, Hanibuchi M, et al. Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer celldepleted SCID mice. Int J Cancer 2004; 108:511-515. (Pubitemid 38036650)
78. Bundred NJ, Walker RA, Ratcliffe WA, et al. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992; 28:690-692.
79. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96:671-675. (Pubitemid 30463390)
80. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581-11586. (Pubitemid 32928771)
81. Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103:2308-2315. (Pubitemid 38326251)
82. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002; 16:1182-1188. (Pubitemid 34618857)
83. Strodel WE, Thompson NW, Eckhauser FE, Knol JA. Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol 1988; 37:10-12. (Pubitemid 18040563)
84. Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 1995; 71:28-31.
85. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981; 50:473-481. (Pubitemid 12162746)
86. LeGrand SB, Leskuski D, Zama I. Furosemide for hypercalcemia: an unproven yet common practice [narrative review]. Ann Intern Med 2008; 149:259-263.
87. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Inter Med 1980; 93:269-272. (Pubitemid 10044710)
88. Dumon JC, Magritte A, Body JJ. Nasal human calcitonin for tumor-induced hypercalcemia. Calcif Tissue Int 1992; 51:18-19.
89. Adachi I, Kimura S, Yamaguchi K, et al. Synthetic salmon calcitonin as an antihypercalcemic agent for hypercalcemia in malignancy. Gan To Kagaku Ryoho 1986; 13:2637-2644. (Pubitemid 17186905)
90. Dunford JE. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr Pharm Des 2010; 16:2961-2969.
91. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10:134-142.
92. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95:297-304. (Pubitemid 23270287)
93. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995; 72:1289-1293.
94. Thiebaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch Inter Med 1990; 150:2125-2128. (Pubitemid 20348364)
95. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558-567. (Pubitemid 32112871)
96. Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003; 11:539-547. (Pubitemid 36994438)
97. Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws -Characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2011. [Epub ahead of print]
98. Mundy GR, Rick ME, Turcotte R, Kowalski MA. Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Am J Med 1978; 65:600-606. (Pubitemid 9114117)
99. Koo WS, Jeon DS, Ahn SJ, et al. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996; 72:424-428. (Pubitemid 26059574)
100. Wang CC, Chen YC, Shiang JC, et al. Hypercalcemic crisis successfully treated with prompt calcium-free hemodialysis. Am J Emerg Med 2009; 27:1174e1-1174e3.
101. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765.
102. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132-5139.